Find a Research Study

Cohort 1: To demonstrate that the proportion of subjects with vision loss is lower for subjects in the Treatment Arm vs the Control Arm. Cohort 2: To demonstrate the ability to salvage the eye and prevent enucleation in the Treatment Arm

This study wants to find out how well the drug tebentafusp works for people with metastatic uveal melanoma who have a genetic marker called HLA-A*0201. The study will also measure tumor DNA in the blood, called W10 ctDNA, to see how the cancer responds to treatment.

The primary objective of this 3-arm clinical trial is to compare progression-free survival (PFS) of LNS8801 + pembrolizumab arm vs Physicians’ Choice (PC) treatment using RECIST 1.1.

This phase 3 study will evaluate the superiority of the fixed dose combination (FDC) of fianlimab + cemiplimab versus the FDC of relatlimab + nivolumab (referred to as Opdualag™) in participants with unresectable locally advanced or metastatic melanoma.

A study to investigate the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes TIL) regimen plus pembrolizumab infusions compared with pembrolizumab infusions alone in participants with untreated, unresectable or metastatic melanoma

To evaluate the efficacy of IMA203 compared with control (investigator's choice)

We want to find out if using RP2 with nivolumab works better than using ipilimumab with nivolumab to help adults with eye cancer that has spread and cannot be removed by surgery live longer.

To compare progression-free survival (PFS) of amivantamab monotherapy versus cetuximab monotherapy in patients with locoregionally incurable or metastatic cutaneous squamous cell carcinoma and an active immunosuppressed condition

The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO7673396. Stage 2 will evaluate preliminary anti-tumor activity of the RDE(s) defined in Stage 1 and ...

This study wants to learn how well the investigational drug IFx-Hu2.0 works as an added treatment before giving pembrolizumab to people with advanced Merkel cell carcinoma.

This is a first-in-human study to learn more about the investigational drug EBC-129. This study will assess the safety and tolerability of EBC-129 when given alone and in combination with pembrolizumab in patients with advanced solid tumors.

This study is testing a new drug called mRNA-4359, given alone or with pembrolizumab. We want to learn how safe these drugs are and find the best dose for people with cancer that has spread, returned, or is hard to treat.

The overall objective of this study is to ultimately develop an improved standard of cancer care by facilitating new clinical trials, new technology, new informatics solutions and "personalized medicine".